FDA issued Bayesian guidance aimed at clinical trial planning, signaling a broader shift toward more flexible statistical approaches for conditions where classic designs can be difficult—such as some cancers and rare diseases. The guidance is expected to help sponsors structure trials more efficiently and potentially reduce development costs. The change matters for trial design teams because Bayesian methods can incorporate prior information and update probabilities as data accrue, enabling alternative decision frameworks compared with purely frequentist endpoints. For biotech programs, this is likely to affect protocol construction, interim analysis plans, and documentation expectations when regulators review evidence packages—particularly in areas with small patient populations or heterogeneous disease courses.